Insmed's valuation with Phase III success was half that of the analysts, and here's our calculation ...?
We had a legitimate reason for needing cash so urgently that we were forced to dilute you by a massive 44% in nine months, which was ...?
Any other guesses as to the explanation Lewis might offer if asked tomorrow morning why Insmed didn't allow a few months for the share price to reposition in line with analyst valuations with the Phase III success before contemplating that second share offering?
Anybody here think he will comment on the need for a third dilution next year?
And before anybody asks - no, I'm not going to waste money in trying to phone in from the UK.
Every time you post you show how novice you are. mdplanets fine posts also laughed at your "analyst power!". For those of us who follow markets, analysts are looking out for no one but themselves. I'll take the top analyst Goldman Sachs, who investors know is a great contrarian indicator.you on the other hand are a clown .Insmeds offering was because - the price was HIGH ! ...you'll see stupid
We've just got to the part where I prove you don't have the slightest clue about whether or not the price of the offering was high - by inviting you to tell us how many patients you expect to be using Arikace four years from now.
Unlike you - I know WHY $9.776 was by far below any reasonable market valuation with Phase III success. Insmed should have delayed the offering until the price repositioned.